Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
Sonnet BioTherapeutics (NASDAQ: SONN) has entered a clinical collaboration agreement with the Sarcoma Oncology Center to conduct a Phase 1/2a study of SON-1210, their bifunctional IL-12/IL-15 fusion protein, in combination with chemotherapy for pancreatic cancer treatment. The study, led by Dr. Sant Chawla and funded by the Sarcoma Oncology Center, aims to address a significant unmet medical need. Preclinical data has shown SON-1210's potential in solid tumor immunotherapy. The collaboration leverages Sonnet's Fully Human Albumin Binding (FHAB®) platform and targets pancreatic cancer, which has increased expression of FcRn and GP60 receptors, and the SPARC complex. SON-1210 has demonstrated increased immune activity and persistence in preclinical models, with no overt toxicity in IND-enabling studies.
Sonnet BioTherapeutics (NASDAQ: SONN) ha stipulato un accordo di collaborazione clinica con il Sarcoma Oncology Center per condurre uno studio di Fase 1/2a su SON-1210, la loro proteina di fusione bifunzionale IL-12/IL-15, in combinazione con la chemioterapia per il trattamento del cancro pancreatic. Lo studio, guidato dal Dr. Sant Chawla e finanziato dal Sarcoma Oncology Center, mira a soddisfare un'importante esigenza medica non soddisfatta. I dati preclinici hanno dimostrato il potenziale di SON-1210 nell'immunoterapia per tumori solidi. La collaborazione sfrutta la piattaforma Fully Human Albumin Binding (FHAB®) di Sonnet e si concentra sul cancro pancreatic, che presenta un'espressione aumentata dei recettori FcRn e GP60, e del complesso SPARC. SON-1210 ha dimostrato un'aumentata attività immunitaria e persistenza in modelli preclinici, senza tossicità evidente negli studi di abilitazione IND.
Sonnet BioTherapeutics (NASDAQ: SONN) ha firmado un acuerdo de colaboración clínica con el Sarcoma Oncology Center para llevar a cabo un estudio de Fase 1/2a sobre SON-1210, su proteína de fusión bifuncional IL-12/IL-15, en combinación con quimioterapia para el tratamiento del cáncer pancreático. El estudio, dirigido por el Dr. Sant Chawla y financiado por el Sarcoma Oncology Center, tiene como objetivo abordar una importante necesidad médica no satisfecha. Los datos preclínicos han mostrado el potencial de SON-1210 en la inmunoterapia de tumores sólidos. La colaboración aprovecha la plataforma Fully Human Albumin Binding (FHAB®) de Sonnet y se enfoca en el cáncer pancreático, que presenta una mayor expresión de los receptores FcRn y GP60, y del complejo SPARC. SON-1210 ha demostrado una actividad inmunológica y persistencia aumentadas en modelos preclínicos, sin toxicidad evidente en los estudios de habilitación IND.
Sonnet BioTherapeutics (NASDAQ: SONN)는 Sarcoma Oncology Center와 임상 협력 계약을 체결하고 SON-1210, 이들의 이중 기능 IL-12/IL-15 융합 단백질을 사용하여 췌장암 치료를 위한 화학요법과 병행하여 1/2a 단계 연구를 수행합니다. 이 연구는 Dr. Sant Chawla가 이끌고 Sarcoma Oncology Center가 자금을 지원하며, 중요한 unmet 의료 필요를 해결하는 것을 목표로 합니다. 전임상 데이터는 SON-1210의 고형 종양 면역요법에서의 잠재력을 보여주었습니다. 이 협력은 Sonnet의 Fully Human Albumin Binding (FHAB®) 플랫폼을 활용하며, FcRn과 GP60 수용체 및 SPARC 복합체의 발현이 증가한 췌장암을 목표로 합니다. SON-1210은 전임상 모델에서 면역 활동과 지속성이 증가했으며, IND 승인 연구에서는 명백한 독성이 없음을 입증했습니다.
Sonnet BioTherapeutics (NASDAQ: SONN) a conclu un accord de collaboration clinique avec le Sarcoma Oncology Center pour mener une étude de Phase 1/2a sur SON-1210, leur protéine de fusion bifonctionnelle IL-12/IL-15, en combinaison avec une chimiothérapie pour le traitement du cancer du pancréas. L'étude, dirigée par le Dr Sant Chawla et financée par le Sarcoma Oncology Center, vise à répondre à un besoin médical non comblé important. Les données précliniques ont montré le potentiel de SON-1210 en immunothérapie des tumeurs solides. La collaboration exploite la plateforme Fully Human Albumin Binding (FHAB®) de Sonnet et cible le cancer du pancréas, qui présente une expression accrue des récepteurs FcRn et GP60, ainsi que du complexe SPARC. SON-1210 a démontré une activité immunitaire et une persistance accrues dans des modèles précliniques, sans toxicité manifeste dans les études de validation IND.
Sonnet BioTherapeutics (NASDAQ: SONN) hat eine klinische Kooperationsvereinbarung mit dem Sarcoma Oncology Center geschlossen, um eine Phase-1/2a-Studie zu SON-1210, ihrem bifunktionalen IL-12/IL-15 Fusionsprotein, in Kombination mit Chemotherapie zur Behandlung von Bauchspeicheldrüsenkrebs durchzuführen. Die Studie, geleitet von Dr. Sant Chawla und finanziert vom Sarcoma Oncology Center, zielt darauf ab, ein erhebliches ungedecktes medizinisches Bedürfnis zu adressieren. Präklinische Daten haben das Potenzial von SON-1210 in der Immuntherapie für solide Tumoren gezeigt. Die Zusammenarbeit nutzt die Fully Human Albumin Binding (FHAB®) Plattform von Sonnet und zielt auf Bauchspeicheldrüsenkrebs ab, der eine erhöhte Expression der FcRn- und GP60-Rezeptoren sowie des SPARC-Komplexes aufweist. SON-1210 hat in präklinischen Modellen eine erhöhte Immunaktivität und Persistenz gezeigt, ohne offensichtliche Toxizität in IND-ermöglichenden Studien.
- Entered clinical collaboration agreement for Phase 1/2a study of SON-1210 in pancreatic cancer
- Study funded by Sarcoma Oncology Center, preserving Sonnet's cash resources
- Preclinical data shows SON-1210's potential in solid tumor immunotherapy
- SON-1210 demonstrated increased immune activity and persistence in preclinical models
- No overt toxicity observed in IND-enabling toxicology studies of SON-1210
- None.
Insights
The collaboration between Sonnet BioTherapeutics and the Sarcoma Oncology Center marks a significant step in pancreatic cancer research. SON-1210, a bifunctional IL-12/IL-15 fusion protein, shows promise in addressing the limitations of previous cytokine therapies. Its albumin-binding capability could enhance tumor targeting and retention, potentially improving efficacy while reducing toxicity.
The combination with NALIRIFOX, an FDA-approved chemotherapy regimen, may offer synergistic benefits. This approach could be groundbreaking, as there are currently no approved immunotherapies for pancreatic cancer. The preclinical data showing increased immune activity and the absence of significant toxicity in non-human primates are encouraging. However, it's important to remember that success in animal models doesn't always translate to human efficacy.
The investigator-initiated Phase 1/2a study design is noteworthy. It allows for cost-effective research while leveraging the expertise of renowned oncologists. The focus on metastatic pancreatic cancer, an area with high unmet medical need, could potentially fast-track development if results are promising.
Key points to monitor include:
- The safety profile, particularly regarding cytokine-related adverse events
- Efficacy markers, especially the role of interferon gamma (IFNγ) as a biomarker
- Tumor response rates compared to historical data for NALIRIFOX alone
While promising, investors should remain cautious as early-stage oncology trials often face challenges in later phases.
This collaboration is strategically significant for Sonnet BioTherapeutics. By partnering with the Sarcoma Oncology Center, Sonnet can advance SON-1210's development while preserving cash resources. This is important for a clinical-stage biotech company, especially in the current economic climate.
The potential market for pancreatic cancer treatments is substantial, with global incidence rising. If successful, SON-1210 could capture a significant share of this market. However, investors should note that:
- The path to market is long and uncertain
- Competitor landscape in immunotherapy is intense
- Sonnet's financial position and burn rate need close monitoring
While positive, this news alone doesn't guarantee long-term success. Investors should watch for future clinical milestones and potential partnerships.
Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy
An Innovative Immuno Oncology Consortium (“IIOC”) led by Oncology experts funded by the Sarcoma Oncology Center will conduct an investigator-initiated Phase 1/2a study of SON-1210 in pancreatic cancer, an indication with significant unmet medical need
Company management recently participated in a Virtual Investor KOL Connect segment with world-renowned leaders in pancreatic cancer development - Sant Chawla, MD and Andrew Hendifar, MD; Access the segments here
PRINCETON, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced it has entered into a Master Clinical Collaboration Agreement (the “Agreement”) with the Sarcoma Oncology Center, to advance the development of SON-1210, the Company’s proprietary, bifunctional version of human Interleukins 12 (IL-12) and 15 (IL-15), configured using Sonnet's Fully Human Albumin Binding (FHAB®) platform, in combination with chemotherapy for the treatment of metastatic pancreatic cancer.
“We are very pleased to enter into this strategic development collaboration to advance SON-1210 with this prestigious organization and in a program that we believe has the potential to address a significant area of unmet need. We expect that this development approach will provide us with valuable information in a high-value cancer indication that will add to our growing body of data, which we believe will potentially drive value in our platform and enable us to preserve cash resources,” commented Pankaj Mohan, Ph.D., Founder and CEO of Sonnet.
Dr. Hendifar, a renowned physician developing new therapies for pancreatic cancer and neuroendocrine tumors and Associate Professor of Medicine, Medical Director – Pancreatic Cancer, Co-Director – Hematology-Oncology Fellowship Program and Medical Director - Gastrointestinal Oncology Disease Research Group at Cedars-Sinai, added, “Pancreatic cancer incidence is growing worldwide and the advancements in the standards of care beyond chemotherapies has been limited. We believe a novel immunotherapy such as SON-1210 offers an exciting opportunity to improve outcomes for patients.”
Under the terms of the Agreement, the IIOC, led by Dr. Sant Chawla, Director of the Sarcoma Oncology Center, in collaboration with Sonnet, will prepare a protocol and conduct an investigator-initiated Phase 1/2a clinical study to evaluate SON-1210 in combination with several chemotherapeutic agents including but not limited to liposomal irinotecan, 5-fluorouracil/leucovorin, and oxaliplatin (“NALIRIFOX”) for the specific treatment of metastatic pancreatic cancer. NALIRIFOX is U.S. FDA-approved for the treatment of metastatic pancreatic cancer in the front-line and refractory settings. Sonnet will provide the study drug, SON-1210, and support services for the planned Phase 1/2a study.
“We are very excited to enter this collaboration with Sonnet. Cancers are hungry for albumin and albumin-bound drugs are taken up preferentially by cancer cells,” added Dr. Chawla, a leading authority in medical treatment and clinical research for bone and soft-tissue sarcomas and sarcoma therapy. “We know this is a validated mechanism for enhancing efficacy and reducing toxicity and there are no immunotherapies approved for pancreatic cancer. SON-1210's dual IL-12, IL-15 approach builds upon the success of SON-1010 in extending the cytokine half-life and turning cold tumors hot, which is being studied at our center as well.”
John Cini, Ph.D., Chief Scientific Officer and a Co-Founder of Sonnet concluded, “Clinical trials using cytokines have had limited success to date due to their short half-lives, the inability to directly target cancer cells, and high rates of adverse events. Sonnet's fully human albumin-binding platform has been specifically designed to address these issues. Based on our FHAB construct, we have shown that we can increase tumor-targeting and retention by 4-5 fold over unmodified cytokines. We are targeting pancreatic cancer, an area with tremendous unmet need, which has increased expression of the FcRn and GP60 receptors, as well as the SPARC complex. SON-1210, our bifunctional IL-12/IL-15 candidate, has been shown to increase immune activity and persistence in preclinical cancer models, and we are excited to initiate human studies with this unique candidate. SON-1210 may act synergistically with NALIRIFOX, the first new chemotherapy approved for front-line pancreatic cancer in over a decade.”
Additionally, the Company recently participated in a Virtual Investor KOL Connect segment with Dr. Chawla and Dr. Hendifar. The KOL Connect segments are now available here.
As previously announced, the Company successfully completed two IND-enabling toxicology studies of SON-1210 in non-human primates (NHPs), which demonstrated no overt toxicity in the GLP study apart from the expected, and mild, on-target changes in hematology and clinical chemistry parameters that resolved completely within 14 to 21 days post-dosing. A significant increase in interferon gamma (IFNγ), which was transient in nature, was noted as early as one day following administration, with no apparent increase in other proinflammatory cytokines. IFNγ is a well-known pharmacodynamic biomarker that is required for anti-tumor efficacy in preclinical models. Other signs of cytokine imbalance, or uncontrolled increase of pro-inflammatory cytokines (including TNF-α, IL-1β, and IL-6) were notably absent from all dose levels tested in the study.
About SON-1210
SON-1210 is an immunotherapeutic bifunctional drug candidate that links unmodified single-chain human IL-12 and human IL-15 with the albumin-binding domain of the single-chain antibody fragment FHAB separating the two cytokines with linkers to avoid steric hindrance. The FHAB single chain was selected to bind well at normal pH, as well as at an acidic pH that is typically found in the tumor microenvironment (TME). The FHAB technology targets tumor and lymphatic tissue, providing a mechanism for dose-sparing, enhanced PK, and an opportunity to improve the safety and efficacy profile of not only IL-12 and IL-15, but a variety of other potent immunomodulators using the platform. We believe these dual-targeting cytokines can orchestrate a robust immune response to many cancers and pathogens, particularly when presented together on the same molecule. Given the types of proteins induced in the TME, such as Secreted Protein Acidic and Rich in Cysteine (SPARC), several types of cancer such as non-small cell lung cancer, melanoma, head and neck cancer, sarcoma, and some gynecological cancers are particularly relevant for this approach. SON-1210 is designed to deliver IL-12 and IL-15 to local tumor tissue, with the intention of turning ‘cold' tumors ‘hot' by stimulating IFNγ, which activates both innate and adaptive immune cells in the TME, as well as increasing the production of Programed Death Ligand 1 (PD-L1) on tumor cells.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s Master Clinical Collaboration Agreement with the Sarcoma Oncology Center, the outcome of the Company’s clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
833-475-8247
SONN@jtcir.com
FAQ
What is the purpose of Sonnet BioTherapeutics' Phase 1/2a study for SON-1210 (SONN)?
Who is funding the Phase 1/2a study of SON-1210 for Sonnet BioTherapeutics (SONN)?
What were the results of the IND-enabling toxicology studies for SON-1210 (SONN)?
How does SON-1210 potentially improve upon previous cytokine therapies for cancer treatment (SONN)?
